Latest From GC Pharma
As South Korean companies jump into the development of vaccines and drugs for the coronavirus, they also call for stronger government support and increased collaboration between the state and private sectors.
US biotech expands 2017 collaboration with Alnylam and inks collaboration with WuXi. Plus deals involving AbbVie, Allergan, Amazon, Thermo Fisher, Qiagen, Boehringer Ingelheim, Trutino, Taiho, Arcus, Eisai, Fuji Yakuhin, Hikma, Glenmark, Hanmi, GC, Bayer, GW.
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.
Chinese venture funding to the US biotech sector has fallen by nearly 60% in the latest sign of cooling in the previously booming bilateral life sciences investment sector.
- OTC, Consumer
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Infectious & Viral Diseases
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Green Cross Corp.
- South Korea
- Pacific Rim
- Parent & Subsidiaries
- GC Pharma
- Senior Management
- Soon-Tae Cho, Pres.
- Contact Info
Phone: (82) 31 260 9300
107, Ihyeon-ro 30 beon-gil, Giheung-gu
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.